We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+17.49%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$261M
AUM Growth
+$30M
Cap. Flow
+$14.5M
Cap. Flow %
5.56%
Top 10 Hldgs %
97.33%
Holding
16
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
BCAX
Bicara Therapeutics
BCAX
+$14.5M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$154M 59.18%
6,068,125
– –
VRNA
2
DELISTED
Verona Pharma
VRNA
$32.1M 12.29%
1,115,352
– –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.69B
$19.7M 7.56%
1,025,000
– –
BCAX
4
Bicara Therapeutics
BCAX
$1.78B
$14.5M 5.55%
+568,919
New +$14.5M
BMEA icon
5
Biomea Fusion
BMEA
$84.6M
$8.07M 3.09%
798,757
– –
GLUE icon
6
Monte Rosa Therapeutics
GLUE
$1.4B
$7.8M 2.99%
1,472,331
– –
CMPS
7
Compass Pathways
CMPS
$1.53B
$6.08M 2.33%
964,500
– –
NUVB icon
8
Nuvation Bio
NUVB
$2.2B
$5.82M 2.23%
2,541,009
– –
PSTX
9
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$2.98M 1.14%
1,043,267
– –
TECX
10
Tectonic Therapeutic
TECX
$529M
$2.55M 0.98%
84,148
– –
CALC icon
11
CalciMedica
CALC
$15.8M
$2.31M 0.88%
521,114
– –
ELEV
12
DELISTED
Elevation Oncology
ELEV
$1.7M 0.65%
2,834,910
– –
OKUR
13
OnKure Therapeutics
OKUR
$154M
$1.51M 0.58%
88,608
– –
MRKR icon
14
Marker Therapeutics
MRKR
$18.8M
$886K 0.34%
314,286
– –
ACRS icon
15
Aclaris Therapeutics
ACRS
$726M
$500K 0.19%
434,455
– –
VIRX
16
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$66.4K 0.03%
288,571
– –

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Aisling Capital Management held 16 positions worth $261M, up 13% from $231M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Aisling Capital Management deployed $14.5M of net new capital in Q3 2024, opening 1 new position. Its largest new stake was Bicara Therapeutics: 568,919 shares worth $14.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's largest Q3 2024 buy was Bicara Therapeutics: 568,919 shares worth $14.5M.
  • Aisling Capital Management's ten largest holdings make up 97% of its $261M portfolio in Q3 2024.
  • Aisling Capital Management opened 1 new position and closed 0 in Q3 2024.
  • Aisling Capital Management's portfolio value rose 13% quarter-over-quarter to $261M.

Based on Aisling Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.